Gene · 2145
Papers1,378
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,378
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reduced EZH1/2 expression in imipridone-treated cells correlates with synergy following combinations with EZH1/2 or HDAC inhibitors in diffuse glioma and other tumors. | Am J Cancer Res | 2025 | 40226473 | PubTator, text mining | PubMed |
| Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding. | Cancer Chemother Pharmacol | 2025 | 40208327 | PubTator, text mining | PubMed |
| Genetic insights into idiopathic pulmonary fibrosis: a multi-omics approach to identify potential therapeutic targets. | J Transl Med | 2025 | 40091050 | PubTator, text mining | PubMed |
| EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. | Cell Stem Cell | 2025 | 40088890 | PubTator, text mining | PubMed |
| Epigenetic enhancement of adoptive T cell immunotherapy. | Cancer Cell | 2025 | 40068593 | PubTator, text mining | PubMed |
| Toll-Interacting Protein Down-Regulation by Cigarette Smoke Exposure Impairs Human Lung Defense against Influenza A Virus Infection. | Am J Pathol | 2025 | 40056974 | PubTator, text mining | PubMed |
| Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance. | Funct Integr Genomics | 2025 | 40048009 | PubTator, text mining | PubMed |
| EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. | Cancer Cell | 2025 | 39983725 | PubTator, text mining | PubMed |
| Histone bivalency in CNS development. | Genes Dev | 2025 | 39880657 | PubTator, text mining | PubMed |
| A conserved switch to less catalytically active Polycomb repressive complexes in non-dividing cells. | Cell Rep | 2025 | 39799569 | PubTator, text mining | PubMed |
| Traffic light at DSB-transit regulation between gene transcription and DNA repair. | FEBS Lett | 2025 | 39333024 | PubTator, text mining | PubMed |
| Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review. | Life (Basel) | 2024 | 39768352 | PubTator, text mining | PubMed |
| Mitochondrial Proteome Defined Molecular Pathological Characteristics of Oncocytic Thyroid Tumors. | Endocr Pathol | 2024 | 39495444 | PubTator, text mining | PubMed |
| Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2024 | 39486433 | PubTator, text mining | PubMed |
| Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. | Lancet Oncol | 2024 | 39486432 | PubTator, text mining | PubMed |
| PRC2-EZH1 contributes to circadian gene expression by orchestrating chromatin states and RNA polymerase II complex stability. | EMBO J | 2024 | 39433902 | PubTator, text mining | PubMed |
| Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges. | J Clin Invest | 2024 | 39403928 | PubTator, text mining | PubMed |
| Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules. | Endocrinol Metab (Seoul) | 2024 | 39397516 | PubTator, text mining | PubMed |
| A novel EZH1/2 dual inhibitor inhibits GCB DLBCL through cell cycle regulation and M2 tumor-associated macrophage polarization. | J Biol Chem | 2024 | 39303914 | PubTator, text mining | PubMed |
| Bayesian sparse regression for exposure-response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma. | CPT Pharmacometrics Syst Pharmacol | 2024 | 39155584 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2145/papers?page=3